Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC.

NPJ Precis Oncol · 2026 · PMC12948958 · PMID 41593317

Europe PMC DOI

hedged sentences

0.0850

closest p · 1.7× alpha

0.0850

boldest claim

The sentences

showed a trendp = 0.085so close (0.05 < p ≤ 0.1)

In multivariable analyses, Hispanic patients also showed a trend toward worse rwOS (HR: 2.19, 95% CI: 0.90–5.35; p = 0.085), while outcomes for Asian patients were more comparable to NHW (HR: 1.60, 95% CI: 0.54–4.77; p = 0.396).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

While adherence among NHB patients was modestly lower (74%) compared to other groups (~86%), this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.